In a matter involving an antitrust counterclaim, a generic pharmaceutical manufacturer alleged that a blockbuster brand manufacturer attempted to monopolize the market and delay entry of the generic product. A CRA expert was retained to analyze market definition, competitive effects, and lost profits damages estimates. The matter settled favorably for our client shortly before trial.
How compulsory licensing shaped innovation in the Xerox case
In a new article published in the Journal of Industrial Economics, CRA’s Robin Mamrak shows that opening up an incumbent’s patent portfolio can promote...